Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out
LENZ Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.44
-7.2% in 3d after detection
Post-detection moves
1h
—
1d
+1.8%
3d
-7.2%
7d
-4.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS